Keyphrases
Chronic Kidney Disease
100%
Baseline Characteristics
100%
Design Characteristics
100%
Aldosterone Synthase
100%
Protocol Study
100%
Empagliflozin
75%
Treatment Duration
50%
Placebo
50%
Mean Standard Deviation
50%
Albumin-to-creatinine Ratio
50%
Renin-angiotensin System Inhibitors
50%
Angiotensin Receptor Blockers
25%
Type 2 Diabetes Mellitus (T2DM)
25%
Clinical Development
25%
Estimated Glomerular Filtration Rate
25%
Angiotensin-converting Enzyme Inhibitor (ACEi)
25%
Change from Baseline
25%
Safety Profile
25%
Aldosterone
25%
Kidney Protection
25%
Safety Potential
25%
White Race
25%
Aldosterone Synthase Inhibitor
25%
Dose Selection
25%
Medicine and Dentistry
Chronic Kidney Disease
100%
Aldosterone Synthase
100%
Empagliflozin
75%
Placebo
50%
Creatinine
50%
Maturity Onset Diabetes of the Young
25%
Glomerular Filtration Rate
25%
Renal Protection
25%
Angiotensin Receptor Antagonist
25%
Renin Angiotensin Aldosterone System
25%
ACE Inhibitor
25%
Aldosterone
25%
Renin-Angiotensin System Inhibitor
25%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Kidney Failure
100%
Aldosterone Synthase
100%
Empagliflozin
75%
Placebo
50%
Creatinine
50%
Angiotensin Receptor Antagonist
25%
Renin
25%
Angiotensin
25%
Non Insulin Dependent Diabetes Mellitus
25%
Dipeptidyl Carboxypeptidase Inhibitor
25%
Aldosterone
25%
Renin-Angiotensin System Inhibitor
25%
Biochemistry, Genetics and Molecular Biology
Aldosterone Synthase
100%
Renin Angiotensin Aldosterone System
66%
Creatinine
66%
Angiotensin-Converting Enzyme
33%
Angiotensin Receptor
33%
Glomerulus Filtration
33%
Aldosterone
33%
Enzyme Inhibitor
33%